Microbix Biosystems Inc. saw its stock price drop by 3.23% in the latest trading session, reflecting ongoing investor concerns.
Microbix Biosystems Inc. (MBX.TO) experienced a decline of 3.23% in its stock price during the last trading session, closing at CA$0.30. This downward movement raises questions about the company's performance and future prospects amidst a challenging market environment.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeAdvertisement
Market cap
$39.88M
52W high
$0.32
52W low
$0.21
1W change
-3.33%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 37.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+37.9% Upside
Current Price
C$0.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
39.4%
Annualized
90-Day Vol
50.0%
Annualized
Trend (90d)
+37.9%
Annualized drift
90d Mean
C$0.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.30 | C$0.26 – C$0.35 |
| 60 trading days | C$0.32 | C$0.26 – C$0.38 |
| 90 trading days | C$0.33 | C$0.26 – C$0.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Microbix's financial health and market strategies, especially given the recent net loss reported in their Q1 results.
Microbix Biosystems Inc. Market Cap: CA$42.6 Million
With a market cap of CA$42.6 million and a profit margin of -38.62%, Microbix faces significant financial challenges that could impact investor confidence.
Bull case
Microbix reported a 13% increase in revenues for Q1 2026, which suggests that there may be potential growth in its core business, despite the current stock performance.
Bear case
The company's ongoing net losses and lack of a dividend yield might deter investors, especially in a market that rewards profitability and returns.
Advertisement
Recent Performance Overview
In the latest trading session, Microbix Biosystems Inc. saw its stock price decrease by 3.23%, closing at CA$0.30. This decline comes amid investor scrutiny following their recent Q1 2026 financial results, which showed a controlled net loss despite a revenue increase.
Market Sentiment and Future Outlook
The negative market reaction may stem from ongoing concerns about Microbix's profitability, highlighted by its significant negative profit margin of -38.62%. Investors are urged to consider the company's strategic plans and how they may address these financial challenges moving forward. For more insights, check out the latest updates on Microbix's Q1 results and their expansion plans.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
